Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LTA4H | P09960 | 2/20 | 0.52 |
| ▸ | CCR1 | P32246 | 5/20 | 0.50 |
| ▸ | NAMPT | P43490 | 1/20 | 0.49 |
| ▸ | CHRM2 | P08172 | 4/20 | 0.47 |
| ▸ | CHRM1 | P11229 | 4/20 | 0.47 |
| ▸ | CHRM3 | P20309 | 4/20 | 0.47 |
| ▸ | CNR1 | P21554 | 1/20 | 0.44 |
| ▸ | CNR2 | P34972 | 1/20 | 0.44 |
| ▸ | CCR2 | P41597 | 1/20 | 0.44 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.44 |
| ▸ | PRKAA2 | P54646 | 1/20 | 0.43 |
| ▸ | TP53 | P04637 | 1/20 | 0.43 |
| ▸ | MAPT | P10636 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18361283 | 0.90 | LTA4H (0.58) | LTA4HCCR1 | |
| SCHEMBL20592114 | 0.87 | ALDH1A1 (0.50) | CCR1NAMPTCCR2KCNH2MAPT | |
| SCHEMBL20592144 | 0.83 | NAMPT (0.48) | LTA4HCCR1NAMPTCHRM2CHRM1 | |
| SCHEMBL11461585 | 0.81 | HCAR3 (0.58) | LTA4HMAPT | |
| SCHEMBL11465510 | 0.81 | HCAR3 (0.58) | LTA4HMAPT | |
| SCHEMBL3476595 | 0.81 | HCAR3 (0.58) | LTA4HMAPT | |
| SCHEMBL11478987 | 0.81 | HCAR3 (0.58) | LTA4HMAPT | |
| SCHEMBL11460577 | 0.81 | HCAR3 (0.58) | LTA4HMAPT | |
| SCHEMBL20592143 | 0.80 | HDAC1 (0.50) | NAMPT | |
| SCHEMBL20592222 | 0.80 | HDAC1 (0.50) | NAMPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20210009519-A1 | HISTONE DEACETYLASE INHIBITORS | BIOMARIN PHARMACEUTICAL INC. | 2021-01-14 | — | — | US | disclosed |
| US-10851058-B2 | Histone deacetylase inhibitors | BIOMARIN PHARMACEUTICAL INC. (US) | 2020-12-01 | — | — | US | disclosed |
| US-10851058-B2 | Histone deacetylase inhibitors | BIOMARIN PHARMACEUTICAL INC. (US) | 2020-12-01 | — | — | US | disclosed |
| US-10308608-B2 | Histone deacetylase inhibitors | BIOMARIN PHARMACEUTICAL INC. (US) | 2019-06-04 | — | — | US | disclosed |
| US-10308608-B2 | Histone deacetylase inhibitors | BIOMARIN PHARMACEUTICAL INC. (US) | 2019-06-04 | — | — | US | disclosed |
| US-20180370915-A1 | HISTONE DEACETYLASE INHIBITORS | BIOMARIN PHARMACEUTICAL INC. | 2018-12-27 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10851058-B2 | Histone deacetylase inhibitors | HDAC1, HDAC2, HDAC3 | LTA4H 2846/4885CCR1 4312/4885NAMPT 263/4885 |
| US-20210009519-A1 | HISTONE DEACETYLASE INHIBITORS | HDAC1, HDAC2, HDAC3 | LTA4H 2846/4885CCR1 4312/4885NAMPT 263/4885 |
| US-20180370915-A1 | HISTONE DEACETYLASE INHIBITORS | HDAC1, HDAC2, HDAC3 | LTA4H 2846/4885CCR1 4312/4885NAMPT 263/4885 |
| US-10308608-B2 | Histone deacetylase inhibitors | HDAC1, HDAC2, HDAC3 | LTA4H 2846/4885CCR1 4312/4885NAMPT 263/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.